C2N Diagnostics
C2N Diagnostics is a molecular diagnostics company dedicated to transforming early diagnosis and treatment of Alzheimer’s disease and related neurodegenerative disorders. Utilizing state-of-the-art mass spectrometry-based technology, they develop blood-based biomarker tests to aid in diagnosis, monitor disease progression, and support clinical research. Their mission is to provide simple, accessible, minimally invasive tests to improve patient care and advance understanding of neurodegeneration.
Industries
Nr. of Employees
medium (51-250)
Patents
Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes
US-12253529-B2
View DetailsMethods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes
US-10261097-B2
View Details
Methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes
US-12253529-B2
View DetailsMethods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders and associated processes
US-10261097-B2
View DetailsProducts
Plasma assay for brain amyloid status (LC‑MS/MS laboratory-developed test)
A targeted LC‑MS/MS plasma assay measuring amyloid-beta peptide ratios and related proteotype features to estimate presence of brain amyloid pathology and support clinical evaluation of cognitive impairment.
Plasma apolipoprotein E (ApoE) proteotype assay
Proteomic measurement to infer apolipoprotein E proteotype/allele status from plasma to inform clinical management when APOE allele information is relevant.
Plasma phospho‑tau (pTau217) quantitative assay
Targeted LC‑MS/MS measurement of phosphorylated tau peptide concentrations in plasma for use in multianalyte algorithms and longitudinal monitoring of tau-related pathology.
Precivity-ApoE
A blood test indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
Precivity-ApoE(TM)
Blood test indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
PrecivityAD2@
Blood test intended for use in patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.
Plasma assay for brain amyloid status (LC‑MS/MS laboratory-developed test)
A targeted LC‑MS/MS plasma assay measuring amyloid-beta peptide ratios and related proteotype features to estimate presence of brain amyloid pathology and support clinical evaluation of cognitive impairment.
Plasma apolipoprotein E (ApoE) proteotype assay
Proteomic measurement to infer apolipoprotein E proteotype/allele status from plasma to inform clinical management when APOE allele information is relevant.
Plasma phospho‑tau (pTau217) quantitative assay
Targeted LC‑MS/MS measurement of phosphorylated tau peptide concentrations in plasma for use in multianalyte algorithms and longitudinal monitoring of tau-related pathology.
Precivity-ApoE
A blood test indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
Precivity-ApoE(TM)
Blood test indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
PrecivityAD2@
Blood test intended for use in patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.
Services
Analytical and biological endpoint services across preclinical through Phase III/IV, including kinetic assays, target engagement studies, PK/PD correlations, dose optimization, trial screening, and longitudinal treatment monitoring.
Collaborative agreements with academic and clinical investigators to incorporate targeted mass spectrometry–based biomarkers into preclinical and clinical research, including support for study design and sample logistics.
Provision of laboratory-developed blood-based diagnostic testing for neurodegenerative disease biomarkers through an accredited clinical laboratory operating under CLIA and CAP and aligned with ISO quality practices.
Analytical and biological endpoint services across preclinical through Phase III/IV, including kinetic assays, target engagement studies, PK/PD correlations, dose optimization, trial screening, and longitudinal treatment monitoring.
Collaborative agreements with academic and clinical investigators to incorporate targeted mass spectrometry–based biomarkers into preclinical and clinical research, including support for study design and sample logistics.
Provision of laboratory-developed blood-based diagnostic testing for neurodegenerative disease biomarkers through an accredited clinical laboratory operating under CLIA and CAP and aligned with ISO quality practices.
Expertise Areas
- Targeted mass spectrometry-based proteomics
- Biomarker assay development and analytical/clinical validation
- Clinical laboratory operations under CLIA/CAP and ISO frameworks
- Bioanalytical support for clinical trials (screening, PK/PD, monitoring)
Key Technologies
- Liquid chromatography–tandem mass spectrometry (LC‑MS/MS)
- Stable isotope-labeled internal standard quantitation
- Immuno-enrichment (immunoprecipitation) for targeted proteomics
- Targeted proteomics and peptide-level quantitation